Promoter Methylation and Low Placental Expression of Metalloproteinase (MMP)-9, Human Leukocyte Antigen (HLA)-G, Vascular Endothelial Growth Factor (VEGF), and Highly Soluble Endoglin (sEng) as Risk Factors for Preeclampsia
Open Access
- 23 February 2026
- journal article
- Published by Secretariat of The Indonesian Biomedical Journal in The Indonesian Biomedical Journal
- Vol. 18 (1) , 67-76
Abstract
BACKGROUND: Dysregulated expressions of metalloproteinase (MMP)-9, human leucocyte antigen (HLA)-G, vascular endothelial growth factor (VEGF), and soluble endoglin (sEng) reflect impaired angiogenesis, immune tolerance, endothelial function, and trophoblast invasion that characterize abnormal placental development in preeclamptic (PE) pregnancies. However, the role of promoter methylation of these markers in linking the pathways to altered protein expression remains unclear. Hence, this study compared promoter methylation and placental expression of MMP-9, HLA-G, VEGF, and sEng between women with PE and normotensive pregnancies, and evaluate their diagnostic performance as potential biomarkers.METHODS: This case–control study included 30 women with PE and 30 controls. Placental tissue samples were collected within 15 minutes postpartum. Placental promoter methylation was assessed using methylation-specific polymerase chain reaction (PCR), and protein expression was measured using enzyme-linked immunosorbent assay (ELISA). Group differences were analyzed, diagnostic accuracy was evaluated using receiver operating characteristic (ROC) curves, and associations were expressed as adjusted odds ratios (AOR).RESULTS: Compared with controls, placentas from women with PE significantly showed higher methylation of HLA-G (58.9% vs. 37.3%) and sEng (6.7% vs. 4.1%), and lower methylation of VEGF (30.4% vs. 48.1%) and MMP-9 (36.1% vs. 44.9%). Expression of MMP-9, HLA-G, and VEGF was significantly reduced, while sEng expression was increased in PE. Multivariate analysis identified HLA-G hypermethylation (AOR 5.36), VEGF hypomethylation (AOR 8.55), sEng methylation (AOR 4.57), low expression of MMP-9, HLA-G, and VEGF, and high sEng expression (AOR 4.77) as independent predictors of PE. sEng expression demonstrated the best discrimination (AUC 0.835), followed by sEng methylation (AUC 0.785) and HLA-G methylation (AUC 0.774).CONCLUSION: PE is associated with distinct placental methylation–expression alterations, with sEng- and HLA-G–related markers showing the strongest diagnostic value.KEYWORDS: preeclampsia, DNA methylation, angiogenesis, MMP-9, HLA-G, sEng, placenta, epigeneticsKeywords
This publication has 28 references indexed in Scilit:
- Epigenetic biomarker for preeclampsia-associated preterm birth and potential preventative medicineEnvironmental Epigenetics, 2024
- Imbalances in circulating angiogenic factors in the pathophysiology of preeclampsia and related disordersAmerican Journal of Obstetrics and Gynecology, 2022
- The role of endoglin and its soluble form in pathogenesis of preeclampsiaMolecular and Cellular Biochemistry, 2021
- Epigenetic processes during preeclampsia and effects on fetal development and chronic healthClinical Science, 2021
- Ten-eleven translocation 2 demethylates the MMP9 promoter, and its down-regulation in preeclampsia impairs trophoblast migration and invasionJournal of Biological Chemistry, 2018
- Matrix Metalloproteinases in Normal Pregnancy and Preeclampsia2017
- Assessment of Serum Vascular Endothelial Growth Factor Levels in Pregnancy-Induced Hypertension PatientsJournal of Pregnancy, 2017
- Hypermethylation of the HLA-G promoter is associated with preeclampsiaMolecular Human Reproduction, 2015
- Soluble fms-like tyrosine kinase 1 and soluble endoglin are elevated circulating anti-angiogenic factors in pre-eclampsiaPregnancy Hypertension, 2012
- Elevated serum levels of vascular endothelial growth factor in patients with preeclampsiaObstetrics & Gynecology, 1995